Ryaltris Nasal Spray Approved for Seasonal Allergic Rhinitis
Ryaltris is a metered, fixed-dose nasal spray that delivers 665mcg of olopatadine hydrochloride and 25mcg of mometasone furoate in each spray.
Rhinitis/rhinorrhea (Intranasal Products)
Novel Nasal Saline Irrigation System Improves Compliance, Allergic Rhinitis Symptoms
Study authors evaluated the impact on compliance and SNOT-20 scores in patients with allergic rhinitis using a novel sinus nasal rinse device.
Steroid Regimens Compared in Patients With Chronic Rhinosinusitis Without Nasal Polyps
Study authors conducted a prospective randomized trial to determine if there is a role for oral steroids in patients who have CRSsNP.
Treating Chronic Rhinosinusitis With Nasal Polyps: Areas of Improvement Identified
Study authors conducted a retrospective analysis over a 5-year period to analyze health care resource utilization among CRSwNP patients and identify areas for quality improvement.
Narcotic Use Linked to More Complications After Pediatric Sinus Surgery
Multivariate analyses showed that the use of narcotic medications was significantly associated with greater 30-day postoperative complications.
Coinfection With SARS-CoV-2, Other Respiratory Pathogens ID’d
Rhinovirus/enterovirus, respiratory syncytial virus, non-SARS-CoV-2 Coronaviridae coinfections detected.
Clinical Guidelines Developed for Managing Nosebleeds
Ongoing active bleeding should be treated with nasal packing; patients should be educated on packing.
FDA to Review Omalizumab for Chronic Rhinosinusitis With Nasal Polyps
The Food and Drug Administration (FDA) has accepted for filing the supplemental Biologics License Application (sBLA) for omalizumab (Genentech) for the treatment of adults with chronic rhinosinusitis with nasal polyps who have had an inadequate response to intranasal corticosteroids. The sBLA includes data from the POLYP 1 and POLYP 2 trials, which showed that treatment…
Are Intranasal Corticosteroids Effective for Non‐Allergic Rhinitis?
Evidence for the effectiveness of intranasal corticosteroids in the management of non-allergic rhinitis appears to be lacking, according to a recently published systematic review.
Positive Results for Xolair in Adults With Chronic Rhinosinusitis with Nasal Polyps
Genentech announced positive topline data from two phase 3 trials, POLYP 1 and POLYP 2, evaluating Xolair (omalizumab) for the treatment of adults with chronic rhinosinusitis with nasal polyps (CRSwNP) who have not adequately responded to intranasal corticosteroids.
